Equities Analysts Issue Forecasts for Repligen Q2 Earnings

Repligen Co. (NASDAQ:RGEN) – Equities researchers at William Blair lowered their Q2 2025 earnings estimates for shares of Repligen in a report issued on Wednesday, April 30th. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $0.41 for the quarter, down from their previous estimate of $0.45. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2025 earnings at $0.40 EPS, Q4 2025 earnings at $0.46 EPS, Q1 2026 earnings at $0.49 EPS and Q2 2026 earnings at $0.57 EPS.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same period in the previous year, the firm posted $0.28 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis.

Several other equities analysts have also recently weighed in on RGEN. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research note on Tuesday. Canaccord Genuity Group cut their target price on Repligen from $170.00 to $150.00 and set a “hold” rating on the stock in a research note on Wednesday, April 16th. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Monday, April 28th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Repligen Stock Performance

Shares of Repligen stock opened at $141.51 on Thursday. The company has a market cap of $7.95 billion, a PE ratio of -277.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The business has a 50 day moving average price of $137.82 and a 200-day moving average price of $145.81.

Insider Activity

In related news, Director Margaret Pax bought 250 shares of the business’s stock in a transaction on Monday, March 17th. The stock was acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ballentine Partners LLC increased its holdings in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares during the period. CIBC Asset Management Inc increased its holdings in shares of Repligen by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares during the period. GAMMA Investing LLC raised its position in shares of Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock valued at $2,087,000 after buying an additional 100 shares during the period. Finally, Utah Retirement Systems grew its position in Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 100 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.